Hansa Medical Interim report April – June 2018
April – June 2018 in brief ›› Long-term follow-up data from the 17 patients treated with imlifidase in the investigator-initiated Phase II study in highly sensitized patients was presented at the 2018 American Transplant Congress in early June by Professor Stanley C. Jordan, M.D., Director of Nephrology, Cedars-Sinai Medical Center. ›› Patients show good renal function and minimal evidence of antibody-mediated rejection (AMR) at a mean 19 months post kidney transplantation, with graft and patient survival at 94%. ›› Two-year follow-up data demonstrate good patient and graft